CRISPR Therapeutics AG (CRSP) is rated Buy, with a 12-month price target of $64.58, driven by CASGEVY's commercial ramp and a robust pipeline. CASGEVY's increasing patient initiations and revenue ...
Research projects in my lab test for how K. kingae responds to various external stimuli and conditions that it might encounter in the human body during an infection. Working directly with the bacteria ...
In back-to-back studies published in Nature, researchers from Purdue University and Columbia University report a naturally evolved gene-editing system that can activate genes, offering an advantage ...